Gaviscon Extra Chewable Tablets
*Company:
Reckitt Benckiser Ireland LimitedStatus:
No Recent UpdateLegal Category:
Supply through general saleActive Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 06 July 2020
File name
Gaviscon Extra Chew Tabs SmPC.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Supply through general sale
Updated on 06 July 2020
File name
Gaviscon Extra Chew Tabs PIL.pdf
Reasons for updating
- Change to section 2 - excipient warnings
Updated on 15 January 2020
File name
Gaviscon Extra Chewable Tablets.pdf
Reasons for updating
- Change to section 6 - manufacturer
Updated on 03 January 2018
File name
PIL_14880_825.pdf
Reasons for updating
- New PIL for new product
Updated on 03 January 2018
Reasons for updating
- Change to section 1 - what the product is used for
Updated on 02 January 2018
Reasons for updating
- New SPC for new product
Legal category:Supply through general sale
Updated on 02 January 2018
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Addition to Section 5:
Formation of a protective barrier (raft)
Effective impediment of gastro-oesophageal reflux may last for up to 4 hours.
Formation of a protective barrier (raft)
Effective impediment of gastro-oesophageal reflux may last for up to 4 hours.
Updated on 14 June 2016
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 4.3 - update to include a reference to section 6.1
Section 4.5 - Addition of thyroid hormones and estramustine as a consideration for interaction with other medicines
Section 4.6 - New data with regards to use during pregnancy
Section 4.8 - Update to format of undesirable effects
Section 10 - update to date of revision of the text
Section 4.5 - Addition of thyroid hormones and estramustine as a consideration for interaction with other medicines
Section 4.6 - New data with regards to use during pregnancy
Section 4.8 - Update to format of undesirable effects
Section 10 - update to date of revision of the text
Updated on 20 August 2014
Reasons for updating
- Introduction of new pack/pack size
Updated on 18 November 2011
Reasons for updating
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Updated section 9 to include date of last renewal. Resulting in update to section 10
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 01st October 2010
Date of last renewal: 26th January 2011
10. DATE OF REVISION OF THE TEXT
November 2011
Updated on 18 January 2011
Reasons for updating
- New SPC for new product
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
None provided
Updated on 14 January 2011
Reasons for updating
- New PIL for new product